Nacystelyn is under clinical development by Galephar Pharmaceutical Research and currently in Phase II for Acne Vulgaris. According to GlobalData, Phase II drugs for Acne Vulgaris have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nacystelyn’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nacystelyn overview

Nacystelyn is under development for chronic obstructive pulmonary disease (COPD) and recalcitrant acne vulgaris.  It is a dry powder administered through inhalation and oral routes. It was also under development for the treatment of cystic fibrosis. It is a lysine salt of N-acetylcysteine.

Galephar Pharmaceutical Research overview

Galephar Pharmaceutical Research is a company dedicated to the improvement of galenic preparations using the most advanced technology in the world. The company is headquartered in Puerto Rico, the US.

For a complete picture of Nacystelyn’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.